Alexander U Brandt1, Svenja Specovius2, Timm Oberwahrenbrock2, Hanna G Zimmermann2, Friedemann Paul3, Fiona Costello4. 1. Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, NeuroCure Clinical Research Center, Charitéplatz 1, 10117 Berlin, Germany. Electronic address: alexander.brandt@charite.de. 2. Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, NeuroCure Clinical Research Center, Charitéplatz 1, 10117 Berlin, Germany. 3. Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, NeuroCure Clinical Research Center, Charitéplatz 1, 10117 Berlin, Germany; Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Neurology, Charitéplatz 1, 10117 Berlin, Germany; Max Delbrück Center for Molecular Medicine and Charité - Universitätsmedizin Berlin, Experimental and Clinical Research Center, Lindenberger Weg 80, 13125 Berlin, Germany. 4. University of Calgary, Department of Clinical Neurosciences, 2500 University Dr. NW, Calgary, Alberta, Canada T2N 1N4; University of Calgary, Department of Surgery, Calgary, Alberta, Canada; Hotchkiss Brain Institute, 3330 Hospital Drive NW, Calgary, Alberta, Canada T2N 4N1.
Abstract
BACKGROUND: To identify the extent of ganglion cell damage after first-time optic neuritis (ON) using the inter-ocular difference between affected and fellow eyes, and whether this approach is able to detect more patients suffering from ganglion cell damage than using absolute values. METHODS: Thirty-four patients with first-time unilateral ON were followed for a median 413 days. Patients underwent optical coherence tomography testing to determine ganglion cell plus inner plexiform layer thickness (GCIP). Ganglion cell loss was quantified as GCIP difference between ON-affected and fellow eyes (inter-GCIP) and was compared against measurements from 93 healthy controls (HC). Visual function was assessed with high contrast visual acuity; and standard automated perimetry-derived measures of mean deviation and foveal threshold. RESULTS: At clinical presentation after median 19 days from symptom onset, 47.1% of patients showed early GCIP thinning in the ON-affected eye based on inter-GCIP. At the last visit acute ON was associated with 16.1 ± 10.0 µm GCIP thinning compared to fellow eyes (p = 3.669e-06). Based on inter-GCIP, 84.9% of ON patients sustained GCIP thinning in their affected eye at the last visit, whereas using absolute values only 71.0% of patients suffered from GCIP thinning (p = 0.002076). Only 32.3% of these patients had abnormal visual function. The best predictor of GCIP thinning as a measure of ON severity at the last visit was worse visual field mean deviation at clinical presentation. CONCLUSION: Inter-ocular GCIP identifies significantly more eyes suffering damage from ON than absolute GCIP, visual fields or visual acuity loss. Effective interventional options are needed to prevent ganglion cell loss.
BACKGROUND: To identify the extent of ganglion cell damage after first-time optic neuritis (ON) using the inter-ocular difference between affected and fellow eyes, and whether this approach is able to detect more patients suffering from ganglion cell damage than using absolute values. METHODS: Thirty-four patients with first-time unilateral ON were followed for a median 413 days. Patients underwent optical coherence tomography testing to determine ganglion cell plus inner plexiform layer thickness (GCIP). Ganglion cell loss was quantified as GCIP difference between ON-affected and fellow eyes (inter-GCIP) and was compared against measurements from 93 healthy controls (HC). Visual function was assessed with high contrast visual acuity; and standard automated perimetry-derived measures of mean deviation and foveal threshold. RESULTS: At clinical presentation after median 19 days from symptom onset, 47.1% of patients showed early GCIP thinning in the ON-affected eye based on inter-GCIP. At the last visit acute ON was associated with 16.1 ± 10.0 µm GCIP thinning compared to fellow eyes (p = 3.669e-06). Based on inter-GCIP, 84.9% of ON patients sustained GCIP thinning in their affected eye at the last visit, whereas using absolute values only 71.0% of patients suffered from GCIP thinning (p = 0.002076). Only 32.3% of these patients had abnormal visual function. The best predictor of GCIP thinning as a measure of ON severity at the last visit was worse visual field mean deviation at clinical presentation. CONCLUSION: Inter-ocular GCIP identifies significantly more eyes suffering damage from ON than absolute GCIP, visual fields or visual acuity loss. Effective interventional options are needed to prevent ganglion cell loss.
Authors: Magí Andorrà; Salut Alba-Arbalat; Anna Camos-Carreras; Iñigo Gabilondo; Elena Fraga-Pumar; Ruben Torres-Torres; Irene Pulido-Valdeolivas; Ana I Tercero-Uribe; Ana M Guerrero-Zamora; Santiago Ortiz-Perez; Irati Zubizarreta; Nuria Sola-Valls; Sara Llufriu; Maria Sepulveda; Eugenia Martinez-Hernandez; Thais Armangue; Yolanda Blanco; Pablo Villoslada; Bernardo Sanchez-Dalmau; Albert Saiz; Elena H Martinez-Lapiscina Journal: JAMA Neurol Date: 2020-02-01 Impact factor: 18.302
Authors: Elia Sechi; Laura Cacciaguerra; John J Chen; Sara Mariotto; Giulia Fadda; Alessandro Dinoto; A Sebastian Lopez-Chiriboga; Sean J Pittock; Eoin P Flanagan Journal: Front Neurol Date: 2022-06-17 Impact factor: 4.086
Authors: Alexander U Brandt; Hanna G Zimmermann; Norman K Gigengack; Frederike C Oertel; Seyedamirhosein Motamedi; Charlotte Bereuter; Ankelien Duchow; Rebekka Rust; Judith Bellmann-Strobl; Klemens Ruprecht; Tanja Schmitz-Hübsch; Friedemann Paul Journal: Sci Rep Date: 2022-10-20 Impact factor: 4.996
Authors: Christian Albert; Janine Mikolajczak; Anja Liekfeld; Sophie K Piper; Michael Scheel; Hanna G Zimmermann; Claus Nowak; Jan Dörr; Judith Bellmann-Strobl; Claudia Chien; Alexander U Brandt; Friedemann Paul; Olaf Hoffmann Journal: BMC Neurol Date: 2020-03-03 Impact factor: 2.474
Authors: Alexander U Brandt; Friedemann Paul; Svenja Specovius; Hanna G Zimmermann; Frederike Cosima Oertel; Claudia Chien; Charlotte Bereuter; Lawrence J Cook; Marco Aurélio Lana Peixoto; Mariana Andrade Fontenelle; Ho Jin Kim; Jae-Won Hyun; Su-Kyung Jung; Jacqueline Palace; Adriana Roca-Fernandez; Alejandro Rubio Diaz; Maria Isabel Leite; Srilakshmi M Sharma; Fereshte Ashtari; Rahele Kafieh; Alireza Dehghani; Mohsen Pourazizi; Lekha Pandit; Anitha Dcunha; Orhan Aktas; Marius Ringelstein; Philipp Albrecht; Eugene May; Caryl Tongco; Letizia Leocani; Marco Pisa; Marta Radaelli; Elena H Martinez-Lapiscina; Hadas Stiebel-Kalish; Mark Hellmann; Itay Lotan; Sasitorn Siritho; Jérôme de Seze; Thomas Senger; Joachim Havla; Romain Marignier; Caroline Tilikete; Alvaro Cobo Calvo; Denis Bernardi Bichuetti; Ivan Maynart Tavares; Nasrin Asgari; Kerstin Soelberg; Ayse Altintas; Rengin Yildirim; Uygur Tanriverdi; Anu Jacob; Saif Huda; Zoe Rimler; Allyson Reid; Yang Mao-Draayer; Ibis Soto de Castillo; Michael R Yeaman; Terry J Smith Journal: BMJ Open Date: 2020-10-29 Impact factor: 2.692